skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Recent news of the Ohio State ruling on the opioid litigation trial against Johnson & Johnson shed new light on the complex opioid addiction crisis in the US [1]. Alongside this high-profile trial, a whole host of pending litigations against opioid drug makers have gained momentum, and news of numerous abatement settlements with opioid manufacturers and distributors has made its way into the headlines as well. As part of the funding from the abatement plans goes towards opioid use disorder (OUD) prevention, addiction treatment, recovery services, and more, what does that mean for the clinical landscape of OUD? Will we see an uptick in the clinical pipeline, and if so, what drug makers are involved and how will the increased activity help address the dire need to combat the mounting opioid epidemic? 

Trialtrove’s recent addition of “Opioid Use Disorder (OUD)” drives this analysis on the current OUD clinical landscape. The scope of OUD coverage includes 143 clinical trials that have completed since January 2015 or are currently ongoing. This is less than 10% of the pain trials (1,714 trials) that involve at least one opioid analgesic during the same period [2], so clearly there is a large unmet need considering that pain patients are the most at-risk population for OUD. Figure 1 summarizes the top 20 drugs in clinical trials for OUD, which shows mainly a mix of naltrexone and reformulations of buprenorphine. 

 

Rescuing_The_Opioid_Crisis 1

 

There was a remarkable increase in trial starts in 2015, as the number of OUD trials jumped from four trials in 2014 to 22 trials in 2015. Although the number of trials came down slightly in 2016, it has maintained in at least the 20s since 2017 to the present year [3].

 

Rescuing_The_Opioid_Crisis_2

 

The increase in OUD trial starts parallels the intensity of lawsuits filed over the years, where major opioid drug makers like Purdue, Pfizer, and Endo began settling allegations against their liabilities as opioid abuse and addiction grew. As some of the settlement money goes to fund opioid abuse recovery programs and public education, we see an increase of trial numbers from 2015 to the present day. The Infographic on A Decade of Opioid Lawsuits and Settlements [4] offers a succinct summary of drug manufacturers and their associated lawsuits and settlements going back over the last 12 years.

The sponsors of OUD trials are largely academic, with Indivior, Alkermes, Braeburn, and US WorldMeds being the few sponsors representing the commercial industry. Interestingly, none of the top opioid drug makers (Purdue, Pfizer, Teva, Endo, etc) have left a notable footprint on development since 2015. Figure 3 displays the top sponsors, regardless of sponsor types, that are associated with a minimum of five trials.

 

Rescuing_The_Opioid_Crisis_3

 

Geographically, almost all OUD trials are taking place within the US, as the sheer scale of the opioid epidemic is unique to this country, where most of the opioid abuse and overdose cases are reported. The distribution of trials in all other countries is spread across several continents.

 

Rescuing_The_Opioid_Crisis_4

 

The majority of the OUD trials are attributed to patients with opioid dependence, as opioid dependence is the main target to deter abuse and addiction. A modest number of trials have involved patients experiencing withdrawal symptoms, as this is an inevitable part of opioid dependence treatment. Although less than 10% of the trials are focused on relapse and overdose, these areas also represent unmet needs in the treatment of OUD.

 

Rescuing_The_Opioid_Crisis_5

 

As lawmakers, academics, and drug companies join forces to address the rapidly growing opioid crisis, every move by opioid manufacturers and distributors is under public scrutiny. This recent addition of “Opioid Use Disorder (OUD)” in Trialtrove brings us competitive insight into the clinical development landscape as more resources pour in to the rescue, driving awareness of OUD and offering hope to those suffering from opioid addictions.

 

References
[1] Pink Sheet (2019) Opioid Trial Preview: The Claims, Defenses, And Last-Minute Maneuvers. Available from: https://pink.pharmaintelligence.informa.com/PS141045/Opioid-Trial-Preview-The-Claims-Defenses-And-LastMinute-Maneuvers [Accessed October 2019].

[2] Trialtrove® [Accessed October 2019].

[3] Note: Trial numbers are limited to those for which a start date is provided in the public domain. The numbers for recent years may also be impacted by delayed reporting of trial activity.

[4] Pink Sheet (2019) Infographic: A Decade Of Opioid Lawsuits And Settlements. Available from: https://pink.pharmaintelligence.informa.com/PS141044/Infographic-A-Decade-Of-Opioid-Lawsuits-And-Settlements [Accessed October 2019].

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。